Search

Your search keyword '"Döring, Yvonne"' showing total 432 results
Start Over Author "Döring, Yvonne"
432 results on '"Döring, Yvonne"'

53. Inflammatory Mediators in Atherosclerotic Vascular Remodeling

Author

Evans, Bryce R, Yerly, Anaïs, van der Vorst, Emiel P C, Baumgartner, Iris, Bernhard, Sarah Maike, Schindewolf, Marc, and Döring, Yvonne

Subjects
cardiovascular system, 610 Medicine & health, Cardiology and Cardiovascular Medicine
Abstract

Frontiers in Cardiovascular Medicine 9, 1-26 (2022). doi:10.3389/fcvm.2022.868934, Published by Frontiers Media, Lausanne

Published
2022
Full Text
View/download PDF

54. Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease.

Author

Sachs, Stephan, Götz, Anna, Finan, Brian, Feuchtinger, Annette, DiMarchi, Richard D., Döring, Yvonne, Weber, Christian, Tschöp, Matthias H., Müller, Timo D., and Hofmann, Susanna M.

Subjects
THORACIC aorta, AORTIC valve, WEIGHT loss, ATHEROSCLEROTIC plaque, SUBCUTANEOUS injections
Abstract

This document is a correction notice for an article published in the journal Cardiovascular Diabetology. The authors have identified errors in Figure 2 and the Results section of the original article. The corrected figure shows the effects of acyl-GIP treatment on dyslipidemia and atherosclerotic plaque formation in male LDLR-/- mice. The authors clarify that acyl-GIP treatment was accompanied by reduced plaque formation within the aortic valve and a trend towards decreased fat streaks along the descending aorta. The correction notice is provided by the authors Stephan Sachs, Anna Götz, and others. [Extracted from the article]

Published
2024
Full Text
View/download PDF

56. MicroRNA-26b Attenuates Platelet Adhesion and Aggregation in Mice

Author

Peters, Linsey J. F., primary, Baaten, Constance C. F. M. J., additional, Maas, Sanne L., additional, Lu, Chang, additional, Nagy, Magdolna, additional, Jooss, Natalie J., additional, Bidzhekov, Kiril, additional, Santovito, Donato, additional, Moreno-Andrés, Daniel, additional, Jankowski, Joachim, additional, Biessen, Erik A. L., additional, Döring, Yvonne, additional, Heemskerk, Johan W. M., additional, Weber, Christian, additional, Kuijpers, Marijke J. E., additional, and van der Vorst, Emiel P. C., additional

Published
2022
Full Text
View/download PDF

57. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences

Author

Martínez-Salazar, Berenice, Holwerda, Melle, Stüdle, Chiara, Piragyte, Indre, Mercader, Nadia, Engelhardt, Britta, Rieben, Robert, Döring, Yvonne, and Swiss National Science Foundation

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first identified in December 2019 as a novel respiratory pathogen and is the causative agent of Corona Virus disease 2019 (COVID-19). Early on during this pandemic, it became apparent that SARS-CoV-2 was not only restricted to infecting the respiratory tract, but the virus was also found in other tissues, including the vasculature. Individuals with underlying pre-existing co-morbidities like diabetes and hypertension have been more prone to develop severe illness and fatal outcomes during COVID-19. In addition, critical clinical observations made in COVID-19 patients include hypercoagulation, cardiomyopathy, heart arrythmia, and endothelial dysfunction, which are indicative for an involvement of the vasculature in COVID-19 pathology. Hence, this review summarizes the impact of SARS-CoV-2 infection on the vasculature and details how the virus promotes (chronic) vascular inflammation. We provide a general overview of SARS-CoV-2, its entry determinant Angiotensin-Converting Enzyme II (ACE2) and the detection of the SARS-CoV-2 in extrapulmonary tissue. Further, we describe the relation between COVID-19 and cardiovascular diseases (CVD) and their impact on the heart and vasculature. Clinical findings on endothelial changes during COVID-19 are reviewed in detail and recent evidence from in vitro studies on the susceptibility of endothelial cells to SARS-CoV-2 infection is discussed. We conclude with current notions on the contribution of cardiovascular events to long term consequences of COVID-19, also known as "Long-COVID-syndrome". Altogether, our review provides a detailed overview of the current perspectives of COVID-19 and its influence on the vasculature. This research was funded by the Swiss National Science Foundation (SNSF) within the National Research Program NRP 78, project ID 4078P0_198297 to YD, BE, NM, and RR. Sí

Published
2022

58. Sex-specific and hormone-related differences in vascular remodeling in atherosclerosis

Author

Yerly, Anaïs, van der Vorst, Emiel P C, Baumgartner, Iris, Bernhard, Sarah Maike, Schindewolf, Marc, and Döring, Yvonne

Subjects
610 Medicine & health
Abstract

Atherosclerosis, a lipid-driven inflammatory disease, is the main underlying cause of cardiovascular diseases (CVDs) both in men and women. Sex-related dimorphisms regarding CVDs and atherosclerosis were observed since more than a decade ago. Inflammatory mediators such as cytokines, but also endothelial dysfunction, vascular smooth muscle cell migration and proliferation lead to vascular remodeling but are differentially affected by sex. Each year a greater number of men die of CVDs compared to women and are also affected by CVDs at an earlier age (40-70 years old) while women develop atherosclerosis-related complications mainly after the menopause (60+ years). The exact biological reasons behind this discrepancy are still not well understood. From the numerous animal studies on atherosclerosis, only a few include both sexes and even less investigate and highlight the sex-specific differences that may arise. Endogenous sex hormones such as testosterone and estrogen modulate the atherosclerotic plaque composition as well as the frequency of such plaques. In men, testosterone seems to act like a double-edged sword as its decrease with aging correlates with an increased risk of atherosclerotic CVDs, while testosterone is also reported to promote inflammatory immune cell recruitment into the atherosclerotic plaque. In premenopausal women estrogen exerts anti-atherosclerotic effects, which decline together with its level after menopause resulting in increased CVD risk in aging women. However, the interplay of sex hormones, sex-specific immune responses and other sex-related factors is still incompletely understood. This review highlights reported sex-differences in atherosclerotic vascular remodeling and the role of endogenous sex-hormones in this process.

Published
2022
Full Text
View/download PDF

64. Sex‐specific and hormone‐related differences in vascular remodelling in atherosclerosis.

Author

Yerly, Anaïs, van der Vorst, Emiel P. C., Baumgartner, Iris, Bernhard, Sarah Maike, Schindewolf, Marc, and Döring, Yvonne

Subjects
VASCULAR remodeling, ATHEROSCLEROTIC plaque, ATHEROSCLEROSIS, VASCULAR smooth muscle, ENDOTHELIUM diseases
Abstract

Atherosclerosis, a lipid‐driven inflammatory disease, is the main underlying cause of cardiovascular diseases (CVDs) both in men and women. Sex‐related dimorphisms regarding CVDs and atherosclerosis were observed since more than a decade ago. Inflammatory mediators such as cytokines, but also endothelial dysfunction, vascular smooth muscle cell migration and proliferation lead to vascular remodelling but are differentially affected by sex. Each year a greater number of men die of CVDs compared with women and are also affected by CVDs at an earlier age (40–70 years old) while women develop atherosclerosis‐related complications mainly after menopause (60+ years). The exact biological reasons behind this discrepancy are still not well‐understood. From the numerous animal studies on atherosclerosis, only a few include both sexes and even less investigate and highlight the sex‐specific differences that may arise. Endogenous sex hormones such as testosterone and oestrogen modulate the atherosclerotic plaque composition and the frequency of such plaques. In men, testosterone seems to act like a double‐edged sword as its decrease with ageing correlates with an increased risk of atherosclerotic CVDs, while testosterone is also reported to promote inflammatory immune cell recruitment into the atherosclerotic plaque. In premenopausal women, oestrogen exerts anti‐atherosclerotic effects, which decline together with its level after menopause resulting in increased CVD risk in ageing women. However, the interplay of sex hormones, sex‐specific immune responses and other sex‐related factors is still incompletely understood. This review highlights reported sex differences in atherosclerotic vascular remodelling and the role of endogenous sex hormones in this process. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

67. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism

Author

Haghikia, Arash, primary, Zimmermann, Friederike, additional, Schumann, Paul, additional, Jasina, Andrzej, additional, Roessler, Johann, additional, Schmidt, David, additional, Heinze, Philipp, additional, Kaisler, Johannes, additional, Nageswaran, Vanasa, additional, Aigner, Annette, additional, Ceglarek, Uta, additional, Cineus, Roodline, additional, Hegazy, Ahmed N, additional, van der Vorst, Emiel P C, additional, Döring, Yvonne, additional, Strauch, Christopher M, additional, Nemet, Ina, additional, Tremaroli, Valentina, additional, Dwibedi, Chinmay, additional, Kränkel, Nicolle, additional, Leistner, David M, additional, Heimesaat, Markus M, additional, Bereswill, Stefan, additional, Rauch, Geraldine, additional, Seeland, Ute, additional, Soehnlein, Oliver, additional, Müller, Dominik N, additional, Gold, Ralf, additional, Bäckhed, Fredrik, additional, Hazen, Stanley L, additional, Haghikia, Aiden, additional, and Landmesser, Ulf, additional

Published
2021
Full Text
View/download PDF

69. Safety and efficacy of currently utilized treatment modalities in the management of patients with PIK3CA-related overgrowth syndrome - a systematic review

Author

Bernhard, Sarah M., Adam, Luise, Atef, Hady, Häberli, Dario, Bramer, Wichor M, Minder, Beatrice, Döring, Yvonne, Laine, Jessica E., Muka, Taulant, Rössler, Jochen, and Baumgartner, Iris

Subjects
020 Library & information sciences, education, 610 Medicine & health, humanities, 360 Social problems & social services
Abstract

BACKGROUND PIK3CA-related overgrowth syndromes (PROS) include a variety of clinical presentations that are associated with hypertrophy of different parts of the body. AIM Perform a systematic literature review to assess the current treatment options and their efficacy and safety in PROS. METHODS A literature search was performed in EMBASE, MEDLINE (Ovid), Web of Science Core Collection, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Google Scholar to retrieve publications on the treatment for hypertrophy in PROS and randomized controlled trials, cohort studies or case series including ≥10 patients reporting were included in the review. Titles, abstracts and full texts were assessed by two reviewers independently. The Risk of Bias (RoB) was assessed using the Newcastle Ottawa Scale. RESULTS 16 articles for the treatment of hypertrophy in PROS patients were included, 13 (81.3%) from clinical retrospective studies and 3 (13.7%) from prospective cohort studies. The ROB grade was low for 2, medium for 12 and high for 2 studies. 13 articles reported surgical treatment, while 3 reported pharmacological treatment using PIK3/mTOR pathway inhibitors in PROS patients. In 3 studies, PROS was defined by a mutation in the PIK3CA gene, while the other studies relied on a clinical definition of PROS. Surgical therapy was beneficial for a specific subgroup of PROS (macrodactyly), but little was reported concerning surgery and potential benefits in other PROS entities. Reported side effects in surgical therapy were mostly prolonged wound healing or scarring. PIK3/mTOR pathway inhibition was beneficial in patients with PROS reducing hypertrophy as well as systemic symptoms. Adverse effects reported included infection, changes in blood count, liver enzymes and metabolic measures. CONCLUSION Surgery is a locally limited treatment option in specific types of PROS. A promising treatment option in PROS is the pharmacological PIK3CA inhibition. However, the level of evidence on treatment of overgrowth in PROS patients is limited.

Published
2021
Full Text
View/download PDF

77. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice

Author

Weber, Christian, Meiler, Svenja, Döring, Yvonne, Koch, Miriam, Drechsler, Maik, Megens, Remco T.A., Rowinska, Zuzanna, Bidzhekov, Kiril, Fecher, Caroline, Ribechini, Eliana, van Zandvoort, Marc A.M.J., Binder, Christoph J., Jelinek, Ivett, Hristov, Mihail, Boon, Louis, Jung, Steffen, Korn, Thomas, Lutz, Manfred B., Förster, Irmgard, Zenke, Martin, Hieronymus, Thomas, Junt, Tobias, and Zernecke, Alma

Published
2011
Full Text
View/download PDF

80. Germ-free housing conditions do not affect aortic root and aortic arch lesion size of late atherosclerotic low-density lipoprotein receptor-deficient mice

Author

Kiouptsi, Klytaimnistra, primary, Pontarollo, Giulia, additional, Todorov, Hristo, additional, Braun, Johannes, additional, Jäckel, Sven, additional, Koeck, Thomas, additional, Bayer, Franziska, additional, Karwot, Cornelia, additional, Karpi, Angelica, additional, Gerber, Susanne, additional, Jansen, Yvonne, additional, Wild, Philipp, additional, Ruf, Wolfram, additional, Daiber, Andreas, additional, Van Der Vorst, Emiel, additional, Weber, Christian, additional, Döring, Yvonne, additional, and Reinhardt, Christoph, additional

Published
2020
Full Text
View/download PDF

82. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.

Author

Haghikia, Arash, Zimmermann, Friederike, Schumann, Paul, Jasina, Andrzej, Roessler, Johann, Schmidt, David, Heinze, Philipp, Kaisler, Johannes, Nageswaran, Vanasa, Aigner, Annette, Ceglarek, Uta, Cineus, Roodline, Hegazy, Ahmed N, Vorst, Emiel P C van der, Döring, Yvonne, Strauch, Christopher M, Nemet, Ina, Tremaroli, Valentina, Dwibedi, Chinmay, and Kränkel, Nicolle

Subjects
ATHEROSCLEROSIS, CHOLESTEROL metabolism, PROPIONIC acid, GUT microbiome, GENE expression
Abstract

Aims Atherosclerotic cardiovascular disease (ACVD) is a major cause of mortality and morbidity worldwide, and increased low-density lipoproteins (LDLs) play a critical role in development and progression of atherosclerosis. Here, we examined for the first time gut immunomodulatory effects of the microbiota-derived metabolite propionic acid (PA) on intestinal cholesterol metabolism. Methods and results Using both human and animal model studies, we demonstrate that treatment with PA reduces blood total and LDL cholesterol levels. In apolipoprotein E−/− (Apoe −/−) mice fed a high-fat diet (HFD), PA reduced intestinal cholesterol absorption and aortic atherosclerotic lesion area. Further, PA increased regulatory T-cell numbers and interleukin (IL)-10 levels in the intestinal microenvironment, which in turn suppressed the expression of Niemann-Pick C1-like 1 (Npc1l1), a major intestinal cholesterol transporter. Blockade of IL-10 receptor signalling attenuated the PA-related reduction in total and LDL cholesterol and augmented atherosclerotic lesion severity in the HFD-fed Apoe −/− mice. To translate these preclinical findings to humans, we conducted a randomized, double-blinded, placebo-controlled human study (clinical trial no. NCT03590496). Oral supplementation with 500 mg of PA twice daily over the course of 8 weeks significantly reduced LDL [−15.9 mg/dL (−8.1%) vs. −1.6 mg/dL (−0.5%), P = 0.016], total [−19.6 mg/dL (−7.3%) vs. −5.3 mg/dL (−1.7%), P = 0.014] and non-high-density lipoprotein cholesterol levels [PA vs. placebo: −18.9 mg/dL (−9.1%) vs. −0.6 mg/dL (−0.5%), P = 0.002] in subjects with elevated baseline LDL cholesterol levels. Conclusion Our findings reveal a novel immune-mediated pathway linking the gut microbiota-derived metabolite PA with intestinal Npc1l1 expression and cholesterol homeostasis. The results highlight the gut immune system as a potential therapeutic target to control dyslipidaemia that may introduce a new avenue for prevention of ACVDs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

84. Interruption of the CXCL13/CXCR5 Chemokine Axis Enhances Plasma IgM Levels and Attenuates Atherosclerosis Development

Author

van der Vorst, Emiel P. C., additional, Daissormont, Isabelle, additional, Aslani, Maria, additional, Seijkens, Tom, additional, Wijnands, Erwin, additional, Lutgens, Esther, additional, Duchene, Johan, additional, Santovito, Donato, additional, Döring, Yvonne, additional, Halvorsen, Bente, additional, Aukrust, Pal, additional, Weber, Christian, additional, Höpken, Uta E., additional, and Biessen, Erik A. L., additional

Published
2019
Full Text
View/download PDF

85. The Microbiota Promotes Arterial Thrombosis in Low-Density Lipoprotein Receptor-Deficient Mice

Author

Kiouptsi, Klytaimnistra, primary, Jäckel, Sven, additional, Pontarollo, Giulia, additional, Grill, Alexandra, additional, Kuijpers, Marijke J. E., additional, Wilms, Eivor, additional, Weber, Christian, additional, Sommer, Felix, additional, Nagy, Magdolna, additional, Neideck, Carlos, additional, Jansen, Yvonne, additional, Ascher, Stefanie, additional, Formes, Henning, additional, Karwot, Cornelia, additional, Bayer, Franziska, additional, Kollar, Bettina, additional, Subramaniam, Saravanan, additional, Molitor, Michael, additional, Wenzel, Philip, additional, Rosenstiel, Philip, additional, Todorov, Hristo, additional, Gerber, Susanne, additional, Walter, Ulrich, additional, Jurk, Kerstin, additional, Heemskerk, Johan W. M., additional, van der Vorst, Emiel P. C., additional, Döring, Yvonne, additional, and Reinhardt, Christoph, additional

Published
2019
Full Text
View/download PDF

86. Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair

Author

Ferraro, Bartolo, primary, Leoni, Giovanna, additional, Hinkel, Rabea, additional, Ormanns, Steffen, additional, Paulin, Nicole, additional, Ortega-Gomez, Almudena, additional, Viola, Joana R., additional, de Jong, Renske, additional, Bongiovanni, Dario, additional, Bozoglu, Tarik, additional, Maas, Sanne L., additional, D’Amico, Michele, additional, Kessler, Thorsten, additional, Zeller, Tanja, additional, Hristov, Michael, additional, Reutelingsperger, Chris, additional, Sager, Hendrik B., additional, Döring, Yvonne, additional, Nahrendorf, Matthias, additional, Kupatt, Christian, additional, and Soehnlein, Oliver, additional

Published
2019
Full Text
View/download PDF

92. FP526VASCULAR CXCR4 LIMITS ATHEROSCLEROSIS BY MAINTAINING ARTERIAL INTEGRITY

Author

Noels, Heidi, primary, Döring, Yvonne, additional, van der Vorst, Emiel, additional, Egea, Virginia, additional, Drechsler, Maik, additional, Schröder, Katrin, additional, Megens, Remco, additional, Klinkhammer, Barbara, additional, Boor, Peter, additional, Schurgers, Leon, additional, van Gorp, Rick, additional, Ries, Christian, additional, Kusters, Pascal, additional, van der Wal, Allard, additional, Hackeng, Tilman, additional, Gäbel, Gabor, additional, Brandes, Ralf, additional, Soehnlein, Oliver, additional, Lutgens, Esther, additional, Vestweber, Dietmar, additional, Teupser, Daniel, additional, Holdt, Lesca, additional, Rader, Daniel, additional, Saleheen, Danish, additional, and Weber, Christian, additional

Published
2018
Full Text
View/download PDF

93. Chronic Intake of the Selective Serotonin Reuptake Inhibitor Fluoxetine Enhances Atherosclerosis

Author

Rami, Martina, primary, Guillamat-Prats, Raquel, additional, Rinne, Petteri, additional, Salvermoser, Melanie, additional, Ring, Larisa, additional, Bianchini, Mariaelvy, additional, Blanchet, Xavier, additional, Megens, Remco T.A., additional, Döring, Yvonne, additional, Walzog, Barbara, additional, Soehnlein, Oliver, additional, Weber, Christian, additional, Faussner, Alexander, additional, and Steffens, Sabine, additional

Published
2018
Full Text
View/download PDF

95. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer Ga-Pentixafor for PET

Author

Hyafil, Fabien, Pelisek, Jaroslav, Laitinen, Iina, Schottelius, Margret, Mohring, Miriam, Döring, Yvonne, Van Der Vorst, Emiel P C, Kallmayer, Michael, Steiger, Katja, Poschenrieder, Andreas, Notni, Johannes, Fischer, Johannes, Baumgartner, Christine, Rischpler, Christoph, Nekolla, Stephan G, Weber, Christian, Eckstein, Hans-Henning, Wester, Hans-Jürgen, and Schwaiger, Markus

Subjects
610 Medicine & health
Abstract

Ga-pentixafor is a radiotracer for PET that binds with nanomolar affinity to CXCR4. The CXCR4 receptor is expressed at the surface of inflammatory cells. The objective of the study was to analyze the ability of radiolabeled pentixafor to detect CXCR4 expression on inflammatory cells present in atherosclerotic plaques of an experimental rabbit model. Atherosclerotic plaques were induced by endothelial abrasion of the right carotid artery and abdominal aorta of 7 rabbits fed an atherogenic diet. Five noninjured rabbits fed a chow diet were used as controls. Rabbits were imaged on a PET/MR system after injection of Ga-pentixafor (15 MBq/kg). Vascular signal was quantified as tissue-to-background ratio (TBR). Biodistribution and autoradiographic studies were performed 1 h after injection of I-pentixafor (7.5 MBq/kg). In addition, blocking studies were performed in 2 atherosclerotic rabbits with preinjection of the CXCR4 inhibitor AMD3100. Tracer uptake was quantified on arterial cryosections using autoradiography and compared with CXCR4 and RAM-11 (macrophage) expression on adjacent histologic sections. One hour after injection of Ga-pentixafor, strong signals were detected in vivo with PET/MR imaging in atherosclerotic plaques of the abdominal aorta and right carotid artery as compared with normal control arteries (mean TBR = 1.95 ± 0.51 vs. 1.22 ± 0.25 and mean TBR = 1.24 ± 0.38 vs. 0.96 ± 0.37, respectively; < 0.05 for both). Blocking studies with preinjection of a CXCR4 inhibitor reduced I-pentixafor uptake in atherosclerotic plaques by approximately 40%. I-pentixafor uptake in the vessel wall on autoradiographies was located in macrophage-rich regions of atherosclerotic plaques and correlated with the intensity of CXCR4 expression on corresponding cryosections ( = 0.61; < 0.05). Ga-pentixafor allows for the noninvasive detection of CXCR4 expression in the vessel wall with PET and emerges as a potential alternative to F-FDG for the assessment of macrophage infiltration in atherosclerotic plaques.

Published
2017
Full Text
View/download PDF

96. Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques

Author

Merckelbach, Sophie, additional, van der Vorst, Emiel, additional, Kallmayer, Michael, additional, Rischpler, Christoph, additional, Burgkart, Rainer, additional, Döring, Yvonne, additional, de Borst, Gert-Jan, additional, Schwaiger, Markus, additional, Eckstein, Hans-Henning, additional, Weber, Christian, additional, and Pelisek, Jaroslav, additional

Published
2018
Full Text
View/download PDF

98. Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity

Author

Döring, Yvonne, primary, Noels, Heidi, additional, van der Vorst, Emiel P.C., additional, Neideck, Carlos, additional, Egea, Virginia, additional, Drechsler, Maik, additional, Mandl, Manuela, additional, Pawig, Lukas, additional, Jansen, Yvonne, additional, Schröder, Katrin, additional, Bidzhekov, Kiril, additional, Megens, Remco T.A., additional, Theelen, Wendy, additional, Klinkhammer, Barbara M., additional, Boor, Peter, additional, Schurgers, Leon, additional, van Gorp, Rick, additional, Ries, Christian, additional, Kusters, Pascal J.H., additional, van der Wal, Allard, additional, Hackeng, Tilman M., additional, Gäbel, Gabor, additional, Brandes, Ralf P., additional, Soehnlein, Oliver, additional, Lutgens, Esther, additional, Vestweber, Dietmar, additional, Teupser, Daniel, additional, Holdt, Lesca M., additional, Rader, Daniel J., additional, Saleheen, Danish, additional, and Weber, Christian, additional

Published
2017
Full Text
View/download PDF

99. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation

Author

von Hundelshausen, Philipp, primary, Agten, Stijn M., additional, Eckardt, Veit, additional, Blanchet, Xavier, additional, Schmitt, Martin M., additional, Ippel, Hans, additional, Neideck, Carlos, additional, Bidzhekov, Kiril, additional, Leberzammer, Julian, additional, Wichapong, Kanin, additional, Faussner, Alexander, additional, Drechsler, Maik, additional, Grommes, Jochen, additional, van Geffen, Johanna P., additional, Li, He, additional, Ortega-Gomez, Almudena, additional, Megens, Remco T. A., additional, Naumann, Ronald, additional, Dijkgraaf, Ingrid, additional, Nicolaes, Gerry A. F., additional, Döring, Yvonne, additional, Soehnlein, Oliver, additional, Lutgens, Esther, additional, Heemskerk, Johan W. M., additional, Koenen, Rory R., additional, Mayo, Kevin H., additional, Hackeng, Tilman M., additional, and Weber, Christian, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results